The collaboration between Nanostring Technologies, Acrobat Genomics, the Illumina Accelerator, and Stanford Medicine is expected to have a positive short-term impact on NSTG's stock price. The partnership aims to discover new drug targets for gene editing-based therapeutics using GeoMx technology, which could lead to improved treatment options for patients suffering from interstitial lung diseases. This collaboration showcases NSTG's innovative technology and its potential applications in the biotech industry, which could attract investor interest and drive the stock price up.